



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Useful links and info when creating/transitioning trials in CTIS

Presented by Ornela Ademi on 09 February 2024
Change Manager
European Medicines Agency

An agency of the European Union





Where to start?


Actions prior to using CTIS

- **EMA account** - any CTIS user needs to have an [EMA account](#)
- **Sponsor organisation is registered in OMS** - Log in to [OMS](#) with your EMA account
- **Sponsor Administrator is registered in IAM** – request the first Sponsor Administrator role in [EMA Account Management](#)
- **Sponsor organisation to register with EudraVigilance** (via Gateway or EudraVigilance (EV) web application (EVWEB)). More information available [here](#).
 - EVWEB enables the submission of a case (i.e., SUSAR) to EudraVigilance. In addition, it allows the registered user(s) to register a new medicinal product in xEVMPD (medicinal product dictionary).
 - For [EudraVigilance](#) access, users should log into the EMA Account Management portal and request a '[EudraVigilance](#) role'. For more details, see the [Registration manual](#).



EMA account

EMA Account Management



Create a new EMA account
Not sure if you have an EMA account?

[Forgot Password?](#)
[Forgot Username?](#)

Organisation Management Service (OMS) [Share](#)

Table of contents

- [What the OMS is for](#)
- [Scope and expansion of the OMS](#)
- [Submitting change requests](#)
- [Using the OMS for business processes](#)

This content applies to human and veterinary medicines.

The European Medicines Agency (EMA) has launched the Organisation Management Service (OMS) to support regulatory activities throughout the European Union (EU).

The OMS manages one of the four domains of [substance](#), [product](#), [organisation](#) and [referential](#) (SPOR) master data in pharmaceutical regulatory processes.

Access the OMS on the **SPOR portal** using the button below:



The SPOR portal is compatible with Internet Explorer (version 10 and above) and Chrome (version 58 and above) web browsers.

The OMS service supports the [implementation of ISO IDMP standards](#) in the EU.

What the OMS is for

The OMS provides a **single source of validated organisation data** that can be used as a reference to

SPOR data management services

Delivering quality data management services for substances, products, organisations and referentials (SPOR) to power EU regulatory activities.

The four SPOR data management services are:



Substance Management Services (SMS)



Product Management Services (PMS)



Organisation Management Services (OMS)



Referentials Management Services (RMS)

OMS and RMS are the first services to go live and they provide the data foundations for PMS and SMS.

SMS and PMS are not currently activated. More information on the [implementation of SPOR data management services](#) is available on the EMA corporate website.

The SPOR portal provides users with the following data management services:

- view, search, export SPOR data;

Access to SPOR

Use the links in the navigation panel above to access OMS and RMS.

Please use the menus in the navigation panel to navigate RMS and OMS with 'read-only' access to SPOR.

You will need an EMA account with SPOR user roles to conduct additional tasks, such as requesting changes to data, translating data or managing user preferences.

If you already have an active account for any EMA-hosted website or online application, you should use the same credentials to log in.

If you do not already have an EMA account, you need to create an EMA account and request the specific SPOR user roles you require.

Please check if you are able to log in before registering as a new user with SPOR.

Create EMA Account

Registered users can log in using the button at the top of the page.

Using SPOR

Welcome to EMA Account Management | Self registration & access management

About EMA Account Management

EMA Account Management is the European Medicines Agency's (EMA) secure online platform where you can request and manage access to EMA applications.

You can use the EMA Account Management portal to:

👤 Create an EMA account (Self-Register) +

👤 Recover your username and password +

✓ Re-activate your account +

✎ Change your contact details +

📄 Request access on behalf of an organisation +

👥 Manage users of your organisation +

🛡️ Access to EMA systems: security principles and responsibilities +

[EMA Account Management](#)

[Adaptive pathways](#)[Advanced therapies](#)[Clinical trials](#)[Compassionate use](#)[Compliance](#)[Data on medicines \(ISO IDMP standards\)](#)[Ethical use of animals](#)[Innovation in medicines](#)[Medicines for older people](#)[Orphan designation](#)[Paediatric medicines](#)[Pharmacovigilance](#)[EudraVigilance](#)[System overview](#)[Registration](#)[Electronic reporting](#)[Access to data](#)

EudraVigilance: **how to register** [← Share](#)

Table of contents

- [Required actions before EudraVigilance registration](#)
- [Registering organisations in production environment](#)
- [Registering organisations in XCOMP environment and managing the account](#)
- [Registering individual users](#)
- [IT vendors and third-party service providers](#)
- [Additional EudraVigilance roles: EVDAS and level 2B access](#)
- [Training and testing requirements](#)
- [Legal framework](#)
- [Stakeholders and obligations](#)
- [Electronic data interchange partners](#)

Pharmaceutical companies holding or applying for a marketing authorisation in the European Economic Area (EEA), sponsors of clinical trials and national competent authorities in the EEA need to register with EudraVigilance for the electronic data interchange of pharmacovigilance information. The registration process is a prerequisite for electronic reporting.

On 26 July 2018, the European Medicines Agency (EMA) integrated the services of EudraVigilance (human) with EMA's Account Management portal and Organisation Management Service (OMS).

All users, including organisations, **need an active EMA account** created through the EMA Account Management portal.

EMA has published a [Registration manual](#) a [registration frequently asked questions document](#) and has updated this page with new information for companies and users wishing to register with, access or manage their account for EudraVigilance (human) **production environment**. For a quick interactive guide to the revised EudraVigilance registration process, see below:

- [Quick interactive guide to EudraVigilance registration process](#)

[Required actions before EudraVigilance registration](#)


[Register with EudraVigilance](#)



GETTING STARTED WITH CTIS: Sponsor Quickguide

As of GoLive on 31st of January 2022, the Clinical Trials Information System (CTIS) becomes the single-entry portal for submitting clinical trials information in the EU, supporting the day-to-day business processes of authorities and sponsors throughout the life-cycle of a clinical trial.

To get started with CTIS, sponsors must decide their user management approach and complete registrations. A transition period applies for sponsors - [Q&A here](#).





General useful information for sponsors

- [CTIS: how to get started and how to transition a trial](#) collection of links for new CTIS users
- [Online modular training](#)
 - Overview of the different modules of Online Training: [Guidance to CTIS training material catalogue](#)
 - Module 02: High-level overview of CTIS workspaces and common system functionalities
 - Module 19: CTIS for SMEs and Academia
- [Sponsor handbook](#)
- [CTR Q&A](#) published by the European Commission under EudraLex volume 10
- [Quick guide for sponsors - Regulation 536/2014 in practice](#)
- Chapter I - Application and application documents at [Set of documents applicable to trials authorised under Regulation EU No 536/2014](#)

[Adaptive pathways](#)[Advanced therapies](#)[Clinical trials](#) [Accelerating Clinical Trials in the EU \(ACT EU\)](#)[Data submission: guidance for sponsors](#)[Reporting safety information during clinical trials](#)[Clinical Trials Regulation](#)[Clinical Trials Information System](#)[Training and support](#) 

Clinical Trials Information System (CTIS): online training modules

[← Share](#)

Table of contents

- [Introduction to CTIS](#)
- [Sponsor workspace](#)
- [Common functionalities for all registered users](#)
- [Authority workspace](#)
- [Searching CTIS as a public user](#)

EMA provides an online modular training programme to help clinical trial sponsors, national competent authorities, ethics committees, European Commission and EMA staff use the Clinical Trials Information System (CTIS). The programme contains modules and audience-targeted materials covering all clinical trial lifecycle stages, from submission through **authorisation to supervision.**

The online training modules are all available on this page. EMA regularly updates and enhances its training materials.

Please consult the documents below for:

Guidance to CTIS training material catalogue

Adaptive pathways

Advanced therapies

Clinical trials ▼

Accelerating Clinical Trials in the EU (ACT EU)

Data submission: guidance for sponsors

Reporting safety information during clinical trials

Clinical Trials Regulation

Clinical Trials Information System

Training and support ▼[Online training modules](#)

Compassionate use

Compliance

Data on medicines (ISO IDMP standards)

Ethical use of animals

Innovation in medicines

Medicines for older people

Orphan designation

Clinical Trials Information System (CTIS): online training modules [◀ Share](#)

Table of contents

- [Introduction to CTIS](#)
- [Sponsor workspace](#)
- [Common functionalities for all registered users](#)
- [Authority workspace](#)
- [Searching CTIS as a public user](#)

EMA provides an online modular training programme to help clinical trial sponsors, national competent authorities, ethics committees, European Commission and EMA staff use the Clinical Trials Information System (CTIS). The programme contains modules and audience-targeted materials covering all clinical trial lifecycle stages, from submission through authorisation to supervision.

The online training modules are all available on this page. EMA regularly updates and enhances its training materials.

Please consult the documents below for:

- a full catalogue of available training modules, organised by clinical trial lifecycle stage;
- the latest new or updated training materials;
- technical system requirements for the best experience with using CTIS.



[Guide to CTIS training material catalogue \(PDF/1.19 MB\)](#)

First published: 23/06/2021
Last updated: 07/02/2022
Version 1.1



[CTIS Training materials - Latest updates \(PDF/514.23 KB\)](#)

First published: 31/05/2021
Last updated: 21/02/2023
Version 1.2 February 2023



- **Module 1:** Introduction to the Clinical Trials Regulation
- **Module 2:** Overview of CTIS workspaces and common system functionalities
- **Module 3:** User Access Management
- **Module 4:** Support with workload management by workspace
- **Module 5:** How to manage a Clinical Trial (*Notifications, Ad hoc assessment, Corrective measures, and Trial results*)
- **Module 6:** Evaluate a Clinical Trial Application (*Selection of Reporting Member State (RMS) and validation of the clinical trial application*)
- **Module 7:** Management of registered users and role matrix
- **Module 8:** Evaluate a Clinical Trial Application: Assessment and Decision-making
- **Module 9:** How to search, view and download a Clinical Trial and a Clinical Trial Application (*Sponsors*)
- **Module 10:** How to create, submit and withdraw a Clinical Trial Application
- **Module 11:** How to respond to Requests For Information received during the evaluation of a Clinical Trial Application
- **Module 12:** Data protection in CTIS
- **Module 13:** Clinical Study Reports submissions
- **Module 14:** Supervise a Clinical Trial – Corrective measures
- **Module 15:** How to search, view and download a Clinical Trial and a Clinical Trial Application (*Authority*)
- **Module 16:** Supervise a Clinical Trial – Inspection records
- **Module 17:** Supervise a Clinical Trial – Ad hoc assessment (*including safety*)
- **Module 18:** How to submit an Annual Safety Report and respond to related Requests for Information
- **Module 19:** CTIS for SMEs and academia
- **Module 20:** Assess an Annual Safety Report
- **Module 21:** Manage Union Controls
- **Module 22:** Introduction to CTIS for Public Users
- **Module 23:** Transition of trials from EudraCT to CTIS
- **Module 24:** Business Intelligence Reporting (*To be developed*)

Introduction to CTIS

[Expand section](#)[Collapse section](#)

Introduction to the Clinical Trials Regulation (Regulation (EU) No 536/2014) (Module 01)

High-level overview of CTIS workspaces and common system functionalities (Module 02)

Sponsor workspace

[Expand section](#)[Collapse section](#)

Create, submit and withdraw a clinical trial (Module 10)

Respond to requests for information received during the evaluation of a clinical trial application (Module 11)

Manage a clinical trial through CTIS (Module 05)

How to create and submit an annual safety report and respond to related requests for information (Module 18)

Clinical study reports submissions (Module 13)

Search, view and download information on clinical trials and clinical trial applications (Module 09)

CTIS for SMEs and Academia (Module 19)

Common functionalities for all registered users

[Expand section](#)[Collapse section](#)

User access management (Module 03)

Management of registered users and role matrix (Module 07)

Data protection in CTIS (Module 12)

Support with workload management (Module 04)

Transitional trials (Module 23)

Authority workspace

Authority workspace

[Expand section](#)[Collapse section](#)

Evaluate a clinical trial application: Selection of reporting Member State (RMS) and validation of the clinical trial application (Module 06)

Evaluate a clinical trial application: Assessment and decision-making (Module 08)

Supervise a clinical trial: Ad hoc assessment (Module 17)

Supervise a clinical trial: Corrective measures (Module 14)

Supervise a clinical trial: Inspection records (Module 16)

Assess an Annual Safety Report (Module 20)

Search, view and download a clinical trial and a clinical trial application (Module 15)

Union Controls in CTIS (Module 21)

Searching CTIS as a public user

Introduction to CTIS for public users (Module 22)

Related EU legislation

- [Clinical Trial Regulation EU No. 536/2014](#)
- [Regulation \(EU\) 2016/679 \(GDPR\)](#)
- [Regulation \(EU\) 2018/1725 \(EUDPR\)](#)

External links

Access the information and secure workspaces in CTIS:

- [Clinical Trials website](#)

Related content

- [Clinical Trials Regulation](#)
- [EMA Clinical Trial Information System \(CTIS\) webinar: dynamic demo of sponsor workspace\(21/09/2020\)](#)
- [Clinical trials in human medicines](#)
- [Support to SMEs](#)
- [Academia](#)

Contact point

High-level overview of CTIS workspaces and common system functionalities (Module 02)

Sponsor workspace

[Expand section](#)[Collapse section](#)

Create, submit and withdraw a clinical trial (Module 10)

Respond to requests for information received during the evaluation of a clinical trial application (Module 11)

Manage a clinical trial through CTIS (Module 05)

How to create and submit an annual safety report and respond to related requests for information (Module 18)

Clinical study reports submissions (Module 13)

Search, view and download information on clinical trials and clinical trial applications (Module 09)

CTIS for SMEs and Academia (Module 19)







Common functionalities for all registered users

[Expand section](#)[Collapse section](#)

User access management (Module 03)

Management of registered users and role matrix (Module 07)



Module 02	High-level overview of CTIS workspaces and common system functionalities
Target audience(s)	<ul style="list-style-type: none"> • Authorities of EU Member States • European Commission • Sponsors • Market authorisation applicants and holders • Members of the public
Topics covered	<ul style="list-style-type: none"> • What CTIS is • The two individual secure workspaces (i.e. authority and sponsor) in CTIS and their functionalities • The public website which will allow members of the public to access detailed information on all <u>clinical trials</u> conducted in the EU, in all official EU languages • The databases and the systems that feed CTIS with data • CTIS functionalities common to the main user categories, namely sponsors, Member States and the European Commission • Goals of the public website and what information members of the public will be able to access
Learning materials	<ul style="list-style-type: none"> • e-learning course (use Chrome browser) •  Quick guide •  Instructor's guide •  Frequently asked questions (FAQs) • Supporting materials: <ul style="list-style-type: none"> ◦  Guide on CTIS common features ◦  List of acronyms ◦  Quick guide: Fill in the blanks exercise • Videos: <ul style="list-style-type: none"> ◦ CTIS technical environment ◦ CTIS common functionalities, Part A ◦ CTIS common functionalities, Part B ◦ CTIS specific functionalities ◦ CTIS public website

Guide on CTIS common features

This document outlines the main CTIS common features available across the various tabs in both Authority and Sponsor workspaces. These features enable users to perform actions supporting their day-to-day business throughout the life cycle of a clinical trial. Users will find a general description of the characteristics of the buttons that support these features and some guidance for the access and navigation in CTIS. Some of the buttons described in this document are in document placeholders and help users to manage the CTA documents. In the last section, users can find some indicative guidelines on how to remove personal information from the properties of documents that upload to their trials in CTIS. The aim of this document is that users can quickly be familiarised with CTIS.

The document is divided in three sections:

Module 02: Online modular training



CTIS cross-system buttons

This section outlines the characteristics of cross-system buttons (dependences, users' permissions, similarities, and locations) and the description of the most common buttons.





Access and Practicalities

This section outlines the CTIS access links and some guidelines for a proper use of CTIS.



How to remove personal information from properties of CTA documents

This section outlines how users can remove personal information from properties of CTA documents that they upload to their trials in CTIS.

Module 19	CTIS for SMEs and academia
Target audience(s)	<ul style="list-style-type: none">• Sponsors (SMEs and academia)
Topics covered	<ul style="list-style-type: none">• Steps of main processes related to the Sponsors activities in CTIS and the roles and permissions involved• CTIS main functionalities for the sponsor workspace• How to search, view, and download a CT and a CTA• How to submit the different types of <u>clinical trial</u> applications and non-substantial modifications• How to create and submit an RFI response, including changes to application• How to manage a CT• How to submit an ASR and how to respond to related RFIs
Learning materials	<ul style="list-style-type: none">•  Quick guide - Introduction: CTIS for SMEs and Academia - Programme - Module 19•  Step-by-step guide: User administration - CTIS Training Programme - Module 19

Introductory guide

CTIS for SMEs and Academia

CTIS Training Programme – Module 19
Version 1.3 – May 2022

Learning Objective

- Remember the steps of main processes related to the Sponsors activities in CTIS and the roles and permissions involved.

Module 19: CTS for SME and Academia

Step-by-step guide

User administration

CTIS Training Programme – Module 19
Version 1.0 – February 2022

Learning Objectives

- Understand the user administration's approach.
- Understand the assignation and request of roles in CTIS.

Clinical Trials Information System (CTIS) - Sponsor Handbook

A compilation of key guidance, technical information, recommendations, and references for getting ready for the use of CTIS

Executive summary

The aim of the EMA CTIS Sponsor Handbook ('Handbook') is to provide clinical trial (CT) sponsors representing pharmaceutical industry, SME (small and medium-sized enterprises), academia, research organisations and other clinical trial sponsor organisations with the information they need to navigate the Clinical Trials Information System (CTIS) - to create and submit clinical trial information to the member states of the European Union as required by the Clinical Trial Regulation [CTR: Regulation (EU) No 536/2014]. The Regulation harmonises the assessment and supervision processes for clinical trials throughout the EU/EEA, via CTIS. CTIS contains the centralised EU portal and database for clinical trials foreseen by the Regulation.

The Handbook addresses key questions on CTIS and provides a compilation and references to key guidance, technical information, recommendations, training materials, and supportive documentation to facilitate the submission and assessment of CTAs and additional information during the lifecycle of a trial.

It has been developed by the European Medicines Agency (EMA) in collaboration with representatives of industry stakeholders.

The Handbook will be revised as more information becomes available, or system functionalities are updated. It is best used in conjunction with the many references to which it points, for example, Volume 10 of the publication 'The rules governing medicinal products in the European Union' that contains guidance documents applying to clinical trials ([EudraLex - Volume 10 - Clinical trials guidelines](#)).



Table of Contents

Executive summary	1
Table of Contents	5
1. What CTIS is and what it does	7
1.1. A brief introduction to CTIS	7
1.2. Overview of Clinical Trial Application (CTA) process in CTIS – from submission to decision and reporting	8
1.3. CTIS go-live date	9
2. Getting access to CTIS – registrations	10
2.1. User self-registration	10
2.1.1. Multi-factor authentication in CTIS	11
2.2. Organisation and Sponsor Administrator registration	11
2.2.1. Organisation registration in OMS	11
2.2.2. Organisation registration locally in CTIS for use in CTIS	13
2.2.3. Sponsor Administrator registration in EMA Account Management portal for use in CTIS	13
3. Management of users and organisations in CTIS	15
3.1. Key user management concepts in CTIS	15
3.2. User roles concept in CTIS	15
3.3. Organisation-centric approach - Sponsor Administrator	16
3.4. Trial-centric approach – Clinical Trial Administrator	17
3.5. Marketing Authorisation Holder (MAH) group of users	18
3.6. CTIS user personas and organisation models	18
4. How to get a clinical trial application started in CTIS	19
4.1. Introduction	19
4.2. Drafting of the clinical trial application dossier	19
4.3. Clinical Trial Application under evaluation	24
4.4. Clinical Trial Application after decision	24
5. Transition from Directive to Clinical Trial Regulation	25
5.1. Transition period	25
5.2. Points to consider on transitional arrangements	27
5.2.1. What trials should not be transitioned	27
5.2.2. Can the trial be transitioned	27
5.2.3. What are the assessment timelines of transitional trials	29
5.3. How to create a transitional trial in CTIS	29
5.4. How to manage trials transitioned to the CTR in CTIS	29
6. Product management in CTIS	30
6.1. Medicinal product registration in XEVMPD	30
6.2. Medicinal product in CTIS extracted from XEVMPD	31
6.3. Adding an authorised medicinal product in CTIS	32
6.4. Adding an unauthorised medicinal product in CTIS	34
6.5. Medicinal product details in CTIS	35



[Sponsor handbook](#)

The rules governing medicinal products in the European Union
VOLUME 10 - Guidance documents applying to clinical trials

CLINICAL TRIALS REGULATION (EU) NO 536/2014

QUESTIONS & ANSWERS

VERSION 6.7

Submitted for discussion to the Expert Group on Clinical Trials and through written procedure to the Clinical Trials Coordination and Advisory Group

Document history:	
Date of discussion by the expert group on Clinical Trials	
Date of discussion by the Clinical Trials Coordination and Advisory Group :	27 November 2023 + written procedure + written requests for changes
Date of publication:	21/12/2023
Supersedes:	6.6
Changes compared to superseded version:	<ul style="list-style-type: none"> - Review of: 289,294,404 (now numbered 290,295,405). - New Q&A 7.2, 7.41. New point 370 - Annex II: PT (Protocol Synopsis, patient facing documents); EE (patient facing documents). - Annex III: HU (email address for part I-related enquiries); FI (websites) ; SE additional
14	

1.	THE SCOPE OF CLINICAL TRIALS REGULATION IN THE EU.....	11
1.1	Question: What are the new characteristics of the Clinical Trials Regulation (EU) No 536/2014 as compared to the Clinical Trials Directive 2001/20/EC?11	
1.2	Question: Till when is the Clinical Trial Directive 2001/20/EC applicable?..	12
1.3	Question: What is a “clinical trial”?.....	12
1.4	Question: what document/data shall be submitted with an application?	13
1.5	How to proceed in case of discrepancies between the CTR and ICH Good clinical practice guidance?	13
1.6	Question: What is a “low-intervention clinical trial”?.....	14
1.7	Question: What can be considered as a “non-interventional study”?	14
1.8	Question: Is the definition of 'medicinal product' relevant for the scope of the Clinical Trials Regulation?.....	15
1.9	Question: What is not considered as “normal clinical practice”?	16
1.10	Question: A study might involve the administration of a medicinal product, while the object of the investigation is not the administered medicinal product, but exclusively the physiology of the body. Are these studies 'clinical trials' as defined in Regulation (EU) No 536/2014?	17
1.11	Question: How does the issue set out in Question 1.6 apply to PET studies? 18	
1.12	Question: A study might involve a medical device – what does this mean in terms of EU regulation of clinical trials?	19
1.13	Question: Is a study addressing the time of surgery a clinical trial, if patients receive otherwise standard treatment with medicines?	20
1.14	Question: Does the Clinical Trials Regulation apply to clinical trials with IMPs which fall under the 'hospital exemption' for advanced therapy medicinal products?	20
1.15	Question: Is an authorised medicinal product used as comparator in a clinical trial considered to be an investigational medicinal product?	20
1.16	Question: What are the regulatory requirements for IMPs?.....	20
1.17	Question: What is considered to be an auxiliary product?	21
1.18	Question: Can a study be considered as clinical trial within the scope of Regulation (EU) No 536/2014 if it starts after administration/exposure of the investigational medicinal product has finished?	21



Registered uses and role matrix

Module 07 (Online modular training): Management of registered users and role matrix

- [Clinical Trial centric approach vs organisation centric approach](#)
- [How to request roles and how to assign roles to register users in CTIS](#)

Module 19 (Online Modular training): CTIS for SMEs and Academia

- [Quick guide - Introduction](#)
- [Step-by-step guide: User administration](#)



Guidance & information on creation of new CTA

Module 10 (Online Modular training): Create, submit, and withdraw a clinical trial

- [e-learning course: initial clinical trial applications](#) (use Chrome browser)
- [e-learning course: other types of clinical trial applications](#) (use Chrome browser)
- [Step-by-step guide](#)
- [Instructor's guide](#)
- [Frequently asked questions \(FAQs\)](#)

Supporting materials:

- [Process puzzle](#)
- [Checklist of required fields per application type](#)



Live demos on creation of new CTA

Bite size talk:

[Initial clinical trial application](#) (including [presentation](#))

Video instructions: How to submit an initial clinical trial application in CTIS

- [Fill in the Form and the MSC sections](#)
- [Fill in the Part I section](#)
- [Fill in the trial details of Part I section](#)
- [Fill in the Sponsor details of Part I section](#)
- [Fill in the Product details of Part I section](#)
- [Fill in the Part II section](#)
- [How to submit a substantial modification in the CTIS Sponsor workspace](#)
- [How to submit an additional Member State concerned application in the CTIS Sponsor workspace](#)


Information on Transitional trials

As of **31 January 2025**, all clinical trials need to be in CTR (CTIS)

Start transition not later than 16 October 2024

- [Guidance for the transition of clinical trials](#) published by European Commission under EudraLex vol. 10
- [CTCG's best practice guide](#) & [cover letter template](#) for sponsors of transitional trials
- Module 23 of the [CTIS online training programme](#)
- Bitesize talk: [How to submit a transitional trial in CTIS](#) (including [presentation](#))
- Bitesize talk: [Transitional trials and additional Member State concerned \(MSC\) application](#) (including [presentation](#))
- Clinical Trials Information System Webinar: [Second Year of Transition](#) (including [presentation](#))

Transitional trials reminder



Create new trial

Full title (English)*
Transitional trial test

Search organisation

Name contains ID starts with City starts with Country

test organisation

+ New organisation Clear Search organisation

ID	Name	Address	City	postCode	country	phone	email
<input checked="" type="radio"/> ORG-100032565	Test Organisation	Olympians Street 12	Athens	111 42	Greece	02000000000	info@testorganisation.com
<input type="radio"/> ORG-100032564	Test Organisation Spain	Santiago Calle 10	Madrid	28001	Spain	0200110000	info@testorganisation-spain.com

1 - 2 of 2

Transition Trial

Cancel Create

Remember to tick the box on the application to indicate that the trial is a transitional trial!

If technical issues during the submission of a transitional trial, raise a ticket with [ServiceNow](#).



Additional supporting material

EMA webpage [CTIS Training and Support](#)

Regular updates on the CTIS Programme (subscribe): [Clinical Trials Highlights](#)



Any questions?

Further information

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Telephone +31 (0)88 781 6000

Send us a question Go to www.ema.europa.eu/contact

Follow us on  **@EMA_News**